Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2017

  • ID: 4311860
  • Report
  • 45 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Novartis AG
  • Trellis Bioscience Inc
  • VBI Vaccines Inc
  • Vical Inc
  • MORE
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2017

Summary:

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. It interacts with host integrin ITGB1, PDGFRA and EGFR that likely serve as post attachment entry receptors. It participates in the fusion of viral and cellular membranes leading to virus entry into the host cell.

Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 1, 1 and 4 respectively. Report covers products from therapy areas Infectious Disease, Oncology and Women's Health which include indications Cytomegalovirus (HHV-5) Infections, Female Contraception, Glioblastoma Multiforme (GBM), Gonorrhea, Human Immunodeficiency Virus (HIV) Infections (AIDS), Medulloblastoma, Simplexvirus (HSV) Infections and Trichomonas Vaginitis.

The latest report Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2017, outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)
  • The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Novartis AG
  • Trellis Bioscience Inc
  • VBI Vaccines Inc
  • Vical Inc
  • MORE
  1. Introduction
  2. Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview
  3. Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development
  13. Astellas Pharma Inc
  14. Novartis AG
  15. Trellis Bioscience Inc
  16. Vakzine Projekt Management GmbH
  17. VBI Vaccines Inc
  18. Vical Inc
  19. Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles
  20. ASP-0113 - Drug Profile
  21. Product Description
  22. Mechanism Of Action
  23. R&D Progress
  24. CSJ-148 - Drug Profile
  25. Product Description
  26. Mechanism Of Action
  27. R&D Progress
  28. CyMVectin - Drug Profile
  29. Product Description
  30. Mechanism Of Action
  31. R&D Progress
  32. PPCM - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. TRL-345 - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. VBI-1501A - Drug Profile
  41. Product Description
  42. Mechanism Of Action
  43. R&D Progress
  44. VBI-1901 - Drug Profile
  45. Product Description
  46. Mechanism Of Action
  47. R&D Progress
  48. VPM-2001 - Drug Profile
  49. Product Description
  50. Mechanism Of Action
  51. R&D Progress
  52. Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products
  53. Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones
  54. Featured News & Press Releases
  55. May 02, 2017: VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study
  56. Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress
  57. Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
  58. Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate
  59. Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe
  60. Sep 20, 2016: Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine (ASP0113) in Kidney Transplant Patients
  61. Sep 20, 2016: VBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of its Preventative Cytomegalovirus Vaccine Candidate
  62. Sep 01, 2016: VBI Vaccines to Present at the Vaccine Congress
  63. Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit
  64. Aug 22, 2016: VBI Vaccines to Continue Enrolling Participants in the Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate Following Successful Data Safety Monitoring Board Review
  65. Jun 23, 2016: VBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate
  66. Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program
  67. Mar 29, 2016: VBI To Present At The World Vaccine Congress Washington
  68. Mar 07, 2016: VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference
  69. Nov 20, 2015: VBI Vaccines Presents Update and New Data Supporting its Glioblastoma Immunotherapy Program at the ESMO Symposium on Immuno-Oncology
  70. Appendix
  71. Methodology
  72. Coverage
  73. Secondary Research
  74. Primary Research
  75. Expert Panel Validation
  76. Contact Us
  77. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Stage and Route of Administration, H1
  8. Number of Products by Stage and Molecule Type, H1
  9. Pipeline by Astellas Pharma Inc, H1
  10. Pipeline by Novartis AG, H1
  11. Pipeline by Trellis Bioscience Inc, H1
  12. Pipeline by Vakzine Projekt Management GmbH, H1
  13. Pipeline by VBI Vaccines Inc, H1
  14. Pipeline by Vical Inc, H1
  15. Dormant Projects, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Routes of Administration, H1
  6. Number of Products by Stage and Routes of Administration, H1
  7. Number of Products by Molecule Types, H1
  8. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Astellas Pharma Inc
  • Novartis AG
  • Trellis Bioscience Inc
  • Vakzine Projekt Management GmbH
  • VBI Vaccines Inc
  • Vical Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll